BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

...III Jennerex Biotherapeutics Inc. JX-594 Recombinant vaccinia virus (TK-deletion plus GM-CSF) Liver cancer Ph II Neotropix Inc....
BioCentury | May 24, 2010
Clinical News

Seneca Valley Virus: Phase II started

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate intravenous NTX-010 in 99 patients. Neotropix Inc....
BioCentury | Nov 20, 2008
Tools & Techniques

Micromanaging oncolytic viruses

...the Department of Virology at the University of Helsinki. Paul Hallenbeck, president and CSO of Neotropix Inc....
...are administered. At the levels we are delivering, the main concern is clearly liver toxicity." Neotropix's...
...Jennerex Biotherapeutics Inc. , San Francisco, Calif. Mayo Clinic College of Medicine , Rochester, Minn. Neotropix Inc....
BioCentury | Nov 20, 2008
Tools & Techniques

Table 1. Oncolytic virus therapies

...G207 HSV modified to produce a toxic metabolite in tumor cells Brain cancer Phase I Neotropix Inc....
BioCentury | Oct 13, 2008
Clinical News

Seneca Valley Virus: Phase I expanded

...107 to 1011 vp/kg of intravenous NTX-010. The product has Orphan designation for neuroendocrine cancers. Neotropix Inc....
BioCentury | Oct 13, 2008
Clinical News

Seneca Valley Virus regulatory update

...FDA granted Orphan Drug designation for Neotropix's NTX-010 to treat neuroendocrine cancers. The naturally occurring oncolytic...
...neuroendocrine cancers. The naturally occurring oncolytic virus is in Phase I testing for the indication. Neotropix Inc....
BioCentury | Sep 29, 2008
Company News

Neotropix management update

Neotropix Inc. , Malvern, Pa. Business: Cancer Hired: Anthony Williams as CMO, formerly VP of medical research at Synta Pharmaceuticals Corp. WIR Staff...
BioCentury | May 22, 2006
Clinical News

Seneca Valley Virus: Phase I started

...Phase I trial in 15 to 25 patients with various types of advanced neuroendocrine cancers. Neotropix Inc....
BioCentury | Dec 20, 2004
Finance

Ebb & Flow

...stabilize transthyretin , a blood protein. Fidelity Biosciences also participated in the deal. Cancer company Neotropix...
BioCentury | Dec 13, 2004
Financial News

Neotropix raises $10 million

Neotropix (Malvern, Penn.) raised $10 million in a series A round co-led by the Aurora Funds; Quaker BioVentures; and VIMAC Milestone Medica. The company said the financing should carry it through Phase I/II trials of...
Items per page:
1 - 10 of 11
BioCentury | Jan 31, 2011
Strategy

Lysing what it sees

...III Jennerex Biotherapeutics Inc. JX-594 Recombinant vaccinia virus (TK-deletion plus GM-CSF) Liver cancer Ph II Neotropix Inc....
BioCentury | May 24, 2010
Clinical News

Seneca Valley Virus: Phase II started

...began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate intravenous NTX-010 in 99 patients. Neotropix Inc....
BioCentury | Nov 20, 2008
Tools & Techniques

Micromanaging oncolytic viruses

...the Department of Virology at the University of Helsinki. Paul Hallenbeck, president and CSO of Neotropix Inc....
...are administered. At the levels we are delivering, the main concern is clearly liver toxicity." Neotropix's...
...Jennerex Biotherapeutics Inc. , San Francisco, Calif. Mayo Clinic College of Medicine , Rochester, Minn. Neotropix Inc....
BioCentury | Nov 20, 2008
Tools & Techniques

Table 1. Oncolytic virus therapies

...G207 HSV modified to produce a toxic metabolite in tumor cells Brain cancer Phase I Neotropix Inc....
BioCentury | Oct 13, 2008
Clinical News

Seneca Valley Virus: Phase I expanded

...107 to 1011 vp/kg of intravenous NTX-010. The product has Orphan designation for neuroendocrine cancers. Neotropix Inc....
BioCentury | Oct 13, 2008
Clinical News

Seneca Valley Virus regulatory update

...FDA granted Orphan Drug designation for Neotropix's NTX-010 to treat neuroendocrine cancers. The naturally occurring oncolytic...
...neuroendocrine cancers. The naturally occurring oncolytic virus is in Phase I testing for the indication. Neotropix Inc....
BioCentury | Sep 29, 2008
Company News

Neotropix management update

Neotropix Inc. , Malvern, Pa. Business: Cancer Hired: Anthony Williams as CMO, formerly VP of medical research at Synta Pharmaceuticals Corp. WIR Staff...
BioCentury | May 22, 2006
Clinical News

Seneca Valley Virus: Phase I started

...Phase I trial in 15 to 25 patients with various types of advanced neuroendocrine cancers. Neotropix Inc....
BioCentury | Dec 20, 2004
Finance

Ebb & Flow

...stabilize transthyretin , a blood protein. Fidelity Biosciences also participated in the deal. Cancer company Neotropix...
BioCentury | Dec 13, 2004
Financial News

Neotropix raises $10 million

Neotropix (Malvern, Penn.) raised $10 million in a series A round co-led by the Aurora Funds; Quaker BioVentures; and VIMAC Milestone Medica. The company said the financing should carry it through Phase I/II trials of...
Items per page:
1 - 10 of 11